Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > More buying

<< Previous

Bullboard Posts

Next >>

Post by scarlet1967on May 06, 2022 9:59am

188 Views

Post# 34661796

More buying

Filings by transaction date

May 03, 2022 (filed on May 05, 2022)
Insider Name:
Holler, Frank

Ownership Type:
Direct Ownership

Securities:
Common Shares

Nature of Transaction:
10 - Acquisition or disposition in the public market

# or value acquired/disposed of:
39,000

Price:
$2.54